Cancer Research PRL Inhibitor Induces the Cleavage of p130Cas  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 36, 4406-4411, December 1, 1976]
© 1976 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mayhew, E.
Right arrow Articles by Dave, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mayhew, E.
Right arrow Articles by Dave, C.

Inhibition of Tumor Cell Growth in Vitro and in Vivo by 1-ß-D-Arabinofuranosylcytosine Entrapped within Phospholipid Vesicles1

E. Mayhew, D. Papahadjopoulos, Y. M. Rustum and C. Dave

Departments of Experimental Pathology [E. M., D. P.], and Medicine A [Y. M. R.] and Grace Cancer Drug Center [Y. M. R., C. D.], Roswell Park Memorial Institute, Buffalo, New York 14263

Phospholipid vesicles have been used as a carrier vehicle to enhance the cytotoxic activity of 1-ß-D-arabinofuranosylcytosine (ara-C) and 1-ß-D-arabinofuranosylcytosine 5'-triphosphate against several tumor cell lines. The activity of both compounds in free solution or entrapped within phospholipid vesicles was compared against L1210 cells, Ehrlich ascites cells, and SV40-transformed 3T3 cells in vitro. In addition, the activity of vesicle-entrapped ara-C against L1210 cells was also studied in vivo. The results obtained in vitro with ara-C indicated no difference in the concentration needed to inhibit growth of cells by 50% between free ara-C and vesicle-entrapped ara-C. In contrast, 1-ß-D-arabinofuranosylcytosine 5'-triphosphate entrapped in phospholipid vesicles was a more potent inhibitor of L1210 in culture (ID50, 2 x 10-8 M) compared to the relatively inactive free 1-ß-D-arabinofuranosylcytosine 5'-triphosphate (ID50, >10-7 M). Experiments carried out with L1210 cells in mice showed that, after a single i.p. dose (10 mg/kg) of vesicle-entrapped ara-C, the average survival times of mice inoculated with 105 L1210 cells were increased by over 90%. In control experiments, free ara-C or vesicles plus free ara-C (10 mg/kg) did not prolong survival of mice.

1 Supported by USPHS Research Grant CA-18524 from the National Cancer Institute.

Received 4/26/76. Accepted 8/25/76.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1976 by the American Association for Cancer Research.